It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Nosocomial infections caused by enterococci are an ongoing global threat. Thus, finding therapeutic agents for the treatment of such infections are crucial. Some Enterococcus faecalis strains are able to produce antimicrobial peptides called bacteriocins. We analyzed 65 E. faecalis isolates from 43 food samples and 22 clinical samples in Egypt for 17 common bacteriocin-encoding genes of Enterococcus spp. These genes were absent in 11 isolates that showed antimicrobial activity putatively due to bacteriocins (three from food, including isolate OS13, and eight from clinical isolates). The food-isolated E. faecalis OS13 produced bacteriocin-like inhibitory substances (BLIS) named enterocin OS13, which comprised two peptides (enterocin OS13α OS13β) that inhibited the growth of antibiotic-resistant nosocomial E. faecalis and E. faecium isolates. The molecular weights of enterocin OS13α and OS13β were determined as 8079 Da and 7859 Da, respectively, and both were heat-labile. Enterocin OS13α was sensitive to proteinase K, while enterocin OS13β was resistant. Characterization of E. faecalis OS13 isolate revealed that it belonged to sequence type 116. It was non-hemolytic, bile salt hydrolase-negative, gelatinase-positive, and sensitive to ampicillin, penicillin, vancomycin, erythromycin, kanamycin, and gentamicin. In conclusion, BLIS as enterocin OS13α and OS13β represent antimicrobial agents with activities against antibiotic-resistant enterococcal isolates.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Beni-Suef University, Microbiology and Immunology Department, Faculty of Pharmacy, Beni Suef, Egypt (GRID:grid.411662.6) (ISNI:0000 0004 0412 4932)
2 Norwegian University of Life Sciences, Department of Chemistry, Biotechnology and Food Science, Laboratory of Microbial Gene Technology and Food Microbiology, Ås, Norway (GRID:grid.19477.3c) (ISNI:0000 0004 0607 975X)
3 Cairo University, Microbiology and Immunology Department and Biotechnology Centre, Faculty of Pharmacy, Cairo, Egypt (GRID:grid.7776.1) (ISNI:0000 0004 0639 9286)
4 Assiut University, Microbiology and Immunology Department, Faculty of Medicine, Asyût, Egypt (GRID:grid.252487.e) (ISNI:0000 0000 8632 679X)
5 Nahda University, Department of Microbiology and Immunology, Beni Suef, Egypt (GRID:grid.442628.e) (ISNI:0000 0004 0547 6200); Egypt Center for Research and Regenerative Medicine, Department of Virology, Cairo, Egypt (GRID:grid.511464.3) (ISNI:0000 0005 0235 0917)